Results 61 to 70 of about 8,016 (76)

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Leukemia and Lymphoma, 2014
Pablo Umana, Christian Klein
exaly  

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Blood, 2014
Guillaume Cartron, Michael Hallek
exaly  

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Molecular Cancer Therapeutics, 2011
Stephane Dalle, Christian Klein, Charles Marie Dumontet   +2 more
exaly  

Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101

Leukemia Research, 2017
Jérôme Kucharczak, Gilles A Salles, Abdel Aouacheria   +2 more
exaly  

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Blood, 2011
Manfred Schwaiger, Karl-Peter Hopfner, Christian Klein   +2 more
exaly  

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Blood, 2012
Gilles A Salles, Noel Jean Milpied, Catherine Thieblemont   +2 more
exaly  

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Blood, 2011
Waleed Alduaij, Jamie Honeychurch, Kazuyuki Shimada   +2 more
exaly  

Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Blood, 2009
Guillaume Cartron, Catherine Thieblemont
exaly  

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial

Blood, 2015
Petra Langerbeins, Anna-Maria Fink, Eugen Tausch   +2 more
exaly  

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Blood, 2016
Sandra Robrecht, Anna-Maria Fink, Kirsten Fischer   +2 more
exaly